The First Direct Structural Evidence of SV2A has Been Revealed Thanks to Protein Tomography(TM), and Published in BBRC

STOCKHOLM, September 9 Sidec AB has together with UCBpublished the first direct structural evidence of the molecular mechanism ofthe Synaptic Vesicle protein 2A (SV2A) in mouse brain tissue. SV2A is theunique brain-binding site of the second generation anti-epileptic druglevetiracetam (LEV; Keppra(R) is a trademark of UCB). The result shows thefirst direct structural proof of the "alternating access model" that has beenproposed for the MFS class of transporter proteins. The "alternating accessmodel" postulates that the trans-membrane MFS class proteins can exist in twodifferent conformations; as a valve that can be open to either side of themembrane. Prior to this Protein Tomography(TM) study, great efforts were madeto prove this mechanism both by x-ray crystallography and indirectly by sitedirected mutagenesis.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080220/294289 )

"Obtaining structures of trans-membrane proteins is notoriouslydifficult, and the success of such endeavours is difficult to predict. Thisstudy demonstrates that Protein Tomography(TM) is well adopted to studystructure, function and flexibility of trans-membrane proteins," says AndersAberg, CSO at Sidec.

The publication is available on-line in the journal Biochemical andBiophysical Research Communications, August 7, 2008.http://www.elsevier.com/locate/ybbrc

About Sidec:

Sidec offers Protein Tomography((TM)) as collaborative contract researchprojects. The multidisciplinary team of experts at Sidec can provide a strongIP strategy and proven product differentiation to the bio-pharmaceuticalindustry. Sidec offers their partners a unique visual guidance for target-lead and CD selection to secure a competitive advantage in the drug designstrategy. More information can be found on our homepage where we continuouslyupdate academic collaborations and industrial partnerships as well as recentpublications.For more information, please contact: Mr. Hans Johansson, CEO Phone: +46(8)560-02-102 E-mail: [email protected] http://www.sidec.com

SOURCE Sidec AB

Latest Press Release on General News

Precision oncology company Flindr Therapeutics announces €20 million Series A financing to advance first-in-class small molecule inhibitors

V-Bio Ventures leads international syndicate which includes Johnson & Johnson Innovation – JJDC, Inc., QBIC Fund, Flanders Future Tech Fund, Curie Capital as well as seed investor...

Rett Syndrome Research Trust Partners with Vivalink to Shift Symptom Assessment Paradigms in Rett Syndrome

Vivalink's remote patient monitoring solutions accelerate research into rare neurological disorder CAMPBELL, Calif. , April 23, 2024 /PRNewswire/ -- Vivalink , a leading pro...

World IBS Day - April 19th: Raising Awareness for Everyone with IBS

Debunking myths about Irritable Bowel Syndrome TORONTO , April 18, 2024 /PRNewswire/ -- IBS is a chronic gastrointestinal disorder with symptoms like abdominal pain, bloating,...

Important step taken on the Canada Disability Benefit in Budget 2024, but funding falls short

More work must be done to lift Canadians with disabilities out of poverty TORONTO , April 17, 2024 /CNW/ - The federal government has taken an important step on the Canada Di...

Hydrinity Accelerated Skin Science Introduces MicroFusion Technology and Expands Facial Skincare Line with PRELUDE Facial Treatment Cleanser and HYDRI-C Vitamin C Moisturizer

The Next Generation Technology with the Power to Transform Skin MONROE, La. , April 15, 2024 /PRNewswire/ -- Hydrinity Accelerated Skin Science announced today the launch of t...